Prognostic value of polycomb proteins EZH2, BMI1 and SUZ12 and histone modification H3K27me3 in colorectal cancer

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Benard, Anne ^a   Goossens Beumer, Inès J ^a   Van Hoesel, Anneke Q ^a   Horati, Hamed ^a   Putter, Hein ^a   Zeestraten, Eliane C M ^a   Van De Velde, Cornelis J H ^a   Kuppen, Peter J K ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BMI1 PROTEIN; HISTONE H3; LYSINE; POLYCOMB GROUP PROTEIN; SUZ12 PROTEIN; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; HISTONE;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CELL NUCLEUS; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HISTONE MODIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOCAL RECURRENCE FREE SURVIVAL; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTIVE VALUE; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; SCORING SYSTEM; SURVIVAL TIME; TISSUE MICROARRAY; COLORECTAL TUMOR; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PROGNOSIS;

AGED; COLORECTAL NEOPLASMS; FEMALE; HISTONES; HUMANS; MALE; MIDDLE AGED; POLYCOMB-GROUP PROTEINS; PROGNOSIS;

EID: 84907200746     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0108265     Document Type: Article

References (42)

1. Edge SB (2010) AJCC Cancer Staging Manual, 7th edition. Springer: New York.
2. Hoeben KW, van Steenbergen LN, van de Wouw AJ, Rutten HJ, van Spronsen DJ, et al. (2013) Treatment and complications in elderly stage III colon cancer patients in the Netherlands. Ann Oncol 24: 974-979.
3. van den Broek CB, Bastiaannet E, Dekker JW, Portielje JE, de Craen AJ, et al. (2013) Time trends in chemotherapy (administration and costs) and relative survival in stage III colon cancer patients - a large population-based study from 1990 to 2008. Acta Oncol 52: 941-949.
4. Benard A, van de Velde CJ, Lessard L, Putter H, Takeshima L, et al. (2013) Epigenetic status of LINE-1 predicts clinical outcome in early-stage rectal cancer. Br J Cancer 109: 3073-3083.
5. de Maat MF, van de Velde CJ, Benard A, Putter H, Morreau H, et al. (2010) Identification of a quantitative MINT locus methylation profile predicting local regional recurrence of rectal cancer. Clin Cancer Res 16: 2811-2818.
6. van Engeland M, Derks S, Smits KM, Meijer GA, Herman JG (2011) Colorectal cancer epigenetics: complex simplicity. J Clin Oncol 29: 1382-1391.
7. Simon JA, Kingston RE (2009) Mechanisms of polycomb gene silencing: knowns and unknowns. Nat Rev Mol Cell Biol 10: 697-708.
8. Aloia L, Di SB, Di CL (2013) Polycomb complexes in stem cells and embryonic development. Development 140: 2525-2534.
9. Oktaba K, Gutierrez L, Gagneur J, Girardot C, Sengupta AK, et al. (2008) Dynamic regulation by polycomb group protein complexes controls pattern formation and the cell cycle in Drosophila. Dev Cell 15: 877-889.
10. Malouf GG, Taube JH, Lu Y, Roysarkar T, Panjarian S, et al. (2013) Architecture of epigenetic reprogramming following Twist1 mediated epithelialmesenchymal transition. Genome Biol 14: R144.
11. Manoranjan B, Wang X, Hallett RM, Venugopal C, Mack SC, et al. (2013) FoxG1 interacts with Bmi1 to regulate self-renewal and tumorigenicity of medulloblastoma stem cells. Stem Cells 31: 1266-1277.
12. Siddique HR, Parray A, Zhong W, Karnes RJ, Bergstralh EJ, et al. (2013) BMI1, stem cell factor acting as novel serum-biomarker for Caucasian and African- American prostate cancer. PLoS One 8: e52993.
13. Allegra E, Puzzo L, Zuccala V, Trapasso S, Vasquez E, et al. (2012) Nuclear BMI-1 expression in laryngeal carcinoma correlates with lymph node pathological status. World J Surg Oncol 10: 206.
14. Gialmanidis IP, Bravou V, Petrou I, Kourea H, Mathioudakis A, et al. (2013) Expression of Bmi1, FoxF1, Nanog, and gamma-catenin in relation to hedgehog signaling pathway in human non-small-cell lung cancer. Lung 191: 511-521.
15. Ruan ZP, Xu R, Lv Y, Tian T, Wang WJ, et al. (2013) Bmi1 knockdown inhibits hepatocarcinogenesis. Int J Oncol 42: 261-268.
16. Yoshikawa R, Tsujimura T, Tao L, Kamikonya N, Fujiwara Y (2012) The oncoprotein and stem cell renewal factor BMI1 associates with poor clinical outcome in oesophageal cancer patients undergoing preoperative chemoradiotherapy. BMC Cancer 12: 461.
17. Behrens C, Solis LM, Lin H, Yuan P, Tang X, et al. (2013) EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma. Clin Cancer Res 19: 6556-6565.
18. Crea F, Fornaro L, Paolicchi E, Masi G, Frumento P, et al. (2012) An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients. Ann Oncol 23: 1207-1213.
19. Holm K, Grabau D, Lovgren K, Aradottir S, Gruvberger-Saal S, et al. (2012) Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes. Mol Oncol 6: 494-506.
20. Mu Z, Li H, Fernandez SV, Alpaugh KR, Zhang R, et al. (2013) EZH2 knockdown suppresses the growth and invasion of human inflammatory breast cancer cells. J Exp Clin Cancer Res 32: 70.
21. Benoit YD, Witherspoon MS, Laursen KB, Guezguez A, Beausejour M, et al. (2013) Pharmacological inhibition of polycomb repressive complex-2 activity induces apoptosis in human colon cancer stem cells. Exp Cell Res 319: 1463-1470.
22. Cui Y, Chen J, He Z, Xiao Y (2013) SUZ12 depletion suppresses the proliferation of gastric cancer cells. Cell Physiol Biochem 31: 778-784.
23. Li H, Cai Q, Wu H, Vathipadiekal V, Dobbin ZC, et al. (2012) SUZ12 promotes human epithelial ovarian cancer by suppressing apoptosis via silencing HRK. Mol Cancer Res 10: 1462-1472.
24. Chen X, Song N, Matsumoto K, Nanashima A, Nagayasu T, et al. (2013) High expression of trimethylated histone H3 at lysine 27 predicts better prognosis in non-small cell lung cancer. Int J Oncol 43: 1467-1480.
25. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, et al. (2005) REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 93: 387-391.
26. Zeestraten EC, Reimers MS, Saadatmand S, Dekker JW, Liefers GJ, et al. (2013) Combined analysis of HLA class I, HLA-E and HLA-G predicts prognosis in colon cancer patients. Br J Cancer.
27. Bender S, Tang Y, Lindroth AM, Hovestadt V, Jones DT, et al. (2013) Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. Cancer Cell 24: 660-672.
28. Hosogane M, Funayama R, Nishida Y, Nagashima T, Nakayama K (2013) Rasinduced changes in H3K27me3 occur after those in transcriptional activity. PLoS Genet 9: e1003698.
29. Maertens GN, El Messaoudi-Aubert S, Racek T, Stock JK, Nicholls J, et al. (2009) Several distinct polycomb complexes regulate and co-localize on the INK4a tumor suppressor locus. PLoS One 4: e6380.
30. Tong Q, He S, Xie F, Mochizuki K, Liu Y, et al. (2014) Ezh2 Regulates Transcriptional and Posttranslational Expression of T-bet and Promotes Th1 Cell Responses Mediating Aplastic Anemia in Mice. J Immunol 192: 5012-5022.
31. van Nes JG, de Kruijf EM, Faratian D, van de Velde CJ, Putter H, et al. (2011) COX2 expression in prognosis and in prediction to endocrine therapy in early breast cancer patients. Breast Cancer Res Treat 125: 671-685.
32. Putter H, Fiocco M, Geskus RB (2007) Tutorial in biostatistics: competing risks and multi-state models. Stat Med 26: 2389-2430.
33. Wang CG, Ye YJ, Yuan J, Liu FF, Zhang H, et al. (2010) EZH2 and STAT6 expression profiles are correlated with colorectal cancer stage and prognosis. World J Gastroenterol 16: 2421-2427.
34. Fluge O, Gravdal K, Carlsen E, Vonen B, Kjellevold K, et al. (2009) Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis. Br J Cancer 101: 1282-1289.
35. Pietersen AM, Horlings HM, Hauptmann M, Langerod A, Ajouaou A, et al. (2008) EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer. Breast Cancer Res 10: R109.
36. Du J, Li Y, Li J, Zheng J (2010) Polycomb group protein Bmi1 expression in colon cancers predicts the survival. Med Oncol 27: 1273-1276.
37. Yonemitsu Y, Imazeki F, Chiba T, Fukai K, Nagai Y, et al. (2009) Distinct expression of polycomb group proteins EZH2 and BMI1 in hepatocellular carcinoma. Hum Pathol 40: 1304-1311.
38. Wu Z, Wang Q, Wang L, Li G, Liu H, et al. (2013) Combined aberrant expression of Bmi1 and EZH2 is predictive of poor prognosis in glioma patients. J Neurol Sci 335: 191-196.
39. Ha SY, Kim SH (2012) Co-expression of Bmi1 and EZH2 as an independent poor prognostic factor in esophageal squamous cell carcinoma. Pathol Res Pract 208: 462-469.
40. Hinz S, Kempkensteffen C, Christoph F, Krause H, Schrader M, et al. (2008) Expression parameters of the polycomb group proteins BMI1, SUZ12, RING1 and CBX7 in urothelial carcinoma of the bladder and their prognostic relevance. Tumour Biol 29: 323-329.
41. Su IH, Dobenecker MW, Dickinson E, Oser M, Basavaraj A, et al. (2005) Polycomb group protein ezh2 controls actin polymerization and cell signaling. Cell 121: 425-436.
42. He A, Shen X, Ma Q, Cao J, von GA, et al. (2012) PRC2 directly methylates GATA4 and represses its transcriptional activity. Genes Dev 26: 37-42.